The Directors of the Company consider, both individually and together as a Board, that they have acted in the way that they consider, in good faith, would be most likely to promote the success of the Group and Company for the benefit of its members as a whole. This statement sets out how the Board has had regard to the matters set out in section 172(1) Companies Act 2006 when performing its duties (“Section 172”) for the year ended 30 June 2024.

Section 172 requires a Director to have regard, amongst other matters, to the:

• likely consequences of any decisions in the long-term
• interests of the Group’s employees
• need to foster the Group’s business relationships with suppliers, customers and others
• impact of the Group’s operations on the community and environment
• desirability of the Group maintaining a reputation for high standards of business conduct
• need to act fairly between members of the Group

Taking into account the requirements under Section 172 and one of the Group’s key values, being ‘partnership inside and out’, the Board identifies the key stakeholders of the UK business being:

i. our patients

ii. our employees

iii. our doctor networks

iv. our regulators

v. our global and local suppliers

vi. our network of private medical insurers and other local NHS partnerships

vii. our research and academic partners

In terms of the key decisions made by the business over the last financial year, the Board have continued to meet on a quarterly basis and focus has been given by the Board to systems improvement within the internal business which affect all of the stakeholders noted above.

Key decisions made by the Board have centred on:

• refinancing of the Group to mitigate foreign exchange risk and provide capital for growth
• restructuring following emergence from Chapter 11 to include the disposal of the Spanish subsidiary group
• a digital e-referral business
• the disposal of a non-core subsidiary business
• engaging with other new systems providers which will improve and enhance the Group’s document management system and treatment planning solution
• positive engagement with all of our Doctors, all of whom are integral to our success

There have been further developments with the platform used to operate the Group’s e-MDT function which will benefit all multidisciplinary team meetings (attended by several of our clinicians) operated across the UK network, and should allow patients to be considered by those teams which operate at a local and national level. Our Doctor networks continue to be integral to our success, and the Board has focused heavily on positive engagement with all of our Doctors during the course of the year.

The Group continues to invest in new equipment and replace aged modalities where required, which forms part of a planned Linac replacement programme which is considered on a centre-by-centre basis. The Group has also planned for the purchase of new equipment to support the commissioning in one new centre for which an agreement for lease has been completed. Such projects are important elements of the Group’s long-term strategy in providing greater access for patients.

New clinical trial agreements have also been approved by the business in an effort to extend access to clinical trials for patients, which should benefit the wider community including but not limited to our research and academic partners.

The Board has continued to promote and encourage all aspects of patient and employee feedback. Surveys are conducted by the people and culture team and additional engagement sessions are arranged and led by members of the senior leadership team who report to the Board. The Board believes that these opportunities to provide feedback allow patients and staff to participate in shaping the development of the business. This approach is also seen as a means of fully understanding how our culture of safety operates at a practical level and also ensures that employees at all levels in the business play a role in promoting and upholding a strong focus on health and safety, for the benefit of the Group and the wider community.

This report was approved by the board on 26 June 2025.